Global Gene Therapy Market Size study & Forecast, by Vector [Viral VectorsNon-viral VectorsBy Delivery Method (In Vivo, Ex Vivo) by Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Ot

Global Gene Therapy Market Size study & Forecast, by Vector [Viral VectorsNon-viral VectorsBy Delivery Method (In Vivo, Ex Vivo) by Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Others), By Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Receptors, Others), and Regional Analysis, 2022-2029

Global Gene Therapy Market is valued at approximately USD 6.2 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 18.6% over the forecast period 2021-2029. An instruction set for a certain function is carried by a gene, a functional hereditary unit of life. The most cutting-edge treatment for blood disorders, chronic illnesses, infectious diseases, and cancer is gene therapy. The term ""gene therapy"" refers to the process of treating a disease by altering, substituting, or enhancing a missing or deficient genetic combination that causes the ailment. To treat or stop the spread of disease, gene therapy entails replacing some or all of a patient's body's damaged genes with healthy ones. Globally rising rates of cancer, uncommon diseases, genetic disorders, and other medical conditions are the major factors fueling the growth of the gene therapy market.

Over the past few years, gene therapy research has gained more attention. Many businesses introduce cutting-edge products to capitalize on market growth prospects. A researcher from the Indiana University School of Medicine received a USD 12 million grant from the national heart, lung, and blood institute in March 2022. The grant will be used to investigate key ideas in a gene therapy strategy for more effective and potentially curative hemophilia therapies. A robust product portfolio, increasing investments by major market participants, a high prevalence of the target diseases, and interest in novel and creative therapies are some factors that affect the growth of the gene therapy industry. In developed nations, sophisticated therapeutic approaches to chronic disorders are being applied. As a result, chemotherapy and other conventional treatment modalities that have unfavorable side effects and long-term consequences are being substituted with this one. Viral vectors, which have low toxicity and high immunogenicity, are increasingly being used in the production of such medications.The high cost of gene treatments, however, is anticipated to somewhat restrain market expansion throughout the forecast period.

The key regions considered for the Global Gene Therapy Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America segment dominated the global gene therapy market in 2020, in terms of revenue, and is estimated to maintain its dominance during the forecast period. Several government organizations are supporting research campaigns around the country, owing to the robust regulatory framework for cellular treatment development and the substantial presence of biopharmaceutical businesses. Europe is expected to grow with the highest CAGR during the forecast period, the availability of reimbursements, the presence of key industry players in the area, and the existence of contemporary healthcare infrastructure are all essential factors promoting the expansion of the gene therapy market in Europe.

Major market player included in this report are:
Amgen Inc.
Biogen Inc.
Bluebird Bio Inc.
Gilead Sciences Inc. (Kite Pharma)
Novartis AG
Orchard Therapeutics
Sibiono GeneTech Co. Ltd
Hoffmann-La Roche Ltd (Spark Therapeutics)
UniQure NV
Abeona Therapeutics Inc.
Recent Developments in the Market:
Sarepta Therapeutics (US) established a partnership with GenEdit in February 2022 to create gene-editing therapeutics to treat neuromuscular illnesses using Sarepta's technology and GenEdit's NanoGalaxy platform.
The FDA approved KYMRIAH for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in May 2022 from Novartis AG (Switzerland).

Global Gene Therapy Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered vectors, Delivery Method, Application, Gene Type, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Vectors:
Viral Vectors
Non-viral Vectors


By Delivery Method:
In Vivo
Ex Vivo

By Application:
Oncological Disorders
Rare Diseases
Cardiovascular Diseases
Neurological Disorders
Infectious Diseases
Others

By Gene Type:
Antigen
Cytokine
Tumor Suppressor
Suicide
Deficiency
Receptors
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
South Korea
RoAPAC
Rest of the WorldCompanies Mentioned
Amgen Inc.
Biogen Inc.
Bluebird Bio Inc.
Gilead Sciences Inc. (Kite Pharma)
Novartis AG
Orchard Therapeutics
Sibiono GeneTech Co. Ltd
Hoffmann-La Roche Ltd (Spark Therapeutics)
UniQure NV
Abeona Therapeutics Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.